Short Interest in GeoVax Labs Inc. (NASDAQ:GOVX) Rises By 218.4%

GeoVax Labs Inc. (NASDAQ:GOVX) saw a large increase in short interest during the month of August. As of August 14th, there was short interest totaling 182,364 shares, an increase of 218.4% from the July 30th total of 57,276 shares. Based on an average trading volume of 200,659 shares, the days-to-cover ratio is currently 0.9 days. Approximately 5.3% of the shares of the company are short sold.

Analysts Set New Price Targets

Several equities research analysts have commented on GOVX shares. Wall Street Zen raised shares of GeoVax Labs from a “sell” rating to a “hold” rating in a report on Sunday, June 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research note on Friday, July 17th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, GeoVax Labs presently has a consensus rating of “Reduce” and a consensus target price of $150.00.

GeoVax Labs Price Performance

GOVX stock traded up $0.08 during midday trading on Thursday, reaching $0.71. The company had a trading volume of 3,415,079 shares, compared to its average volume of 2,158,241. GeoVax Labs has a 1 year low of $0.59 and a 1 year high of $19.20. The company has a market capitalization of $2.46 million, a P/E ratio of -0.06 and a beta of 3.73. The firm has a 50-day moving average price of $0.94 and a 200-day moving average price of $1.40.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings data on Monday, July 27th. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($2.16) by $1.19. On average, equities analysts predict that GeoVax Labs will post -4.94 EPS for the current year.

Institutional Investors Weigh In On GeoVax Labs

Large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC bought a new position in shares of GeoVax Labs during the 4th quarter valued at about $104,000. Jane Street Group LLC bought a new stake in GeoVax Labs in the 4th quarter worth approximately $99,000. Armistice Capital LLC bought a new stake in GeoVax Labs in the 3rd quarter worth approximately $253,000. BlackRock Inc. purchased a new stake in GeoVax Labs in the second quarter worth approximately $43,857,000. Finally, HRT Financial LP purchased a new stake in GeoVax Labs in the fourth quarter worth approximately $31,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.